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Summary
Background Acne is a common chronic inﬂammatory dermatosis of the piloseba-
ceous unit. It is characterized by seborrhoea, comedone formation and an inﬂam-
matory response consistent with defective cellular immunity to Propionibacterium
acnes.
Objectives The objective of this study was to investigate the immune reactivity of
patients with acne compared with healthy controls by examining the response of
peripheral blood mononuclear cells (PBMCs) to stimulation with P. acnes. Particu-
lar focus was placed upon measuring the production of interleukin (IL)-10,
which has an established immunoregulatory role.
Patients and methods Venous blood was collected from 47 patients with acne and 40
age- and sex-matched healthy controls with no prior history of acne. PBMCs
were cultured and their cytokine response to P. acnes investigated.
Results Pro-inﬂammatory IL-8 and tumour necrosis factor (TNF)-a secretion
from PBMCs was higher in patients with acne when stimulated with P. acnes.
In contrast, a statistically signiﬁcant reduction in PBMC secretion of
anti-inﬂammatory IL-10 in patients with acne was identiﬁed. The impaired
production of IL-10 by PBMCs from patients with acne was conﬁned to
CD14+ cells presumed to be monocytes. The ability of CD14 cells from
patients with acne to phagocytose P. acnes bacteria was also observed to be
defective but the addition of exogenous IL-10 to PBMC cultures restored phago-
cytic activity.
Conclusions These data suggest that patients with acne have a pro-inﬂammatory
cytokine milieu and crucially are unable to contain early inﬂammatory changes
due to a speciﬁc defect in immunosurveillance, namely low monocyte IL-10 pro-
duction. Our observations raise the possibility that acne therapeutics might proﬁt-
ably target IL-10 both as a regulator of pro-inﬂammatory cytokines and in
augmenting the CD14+ cell phagocytic response.
Acne vulgaris is a very common dermatosis1 characterized by
an inﬂammatory reaction in the pilosebaceous follicles of the
face and trunk. It is associated with androgen-mediated sebor-
rhoea, ductal hypercorniﬁcation and the production of inﬂam-
matory mediators by Propionibacterium acnes and ⁄or P. granulosum
trapped within the duct by a corniﬁed plug.2 The cellular
inﬁltrate around early inﬂamed lesions and also healthy-look-
ing follicles in acne-prone skin comprises predominantly
CLA+ T-helper (Th) 1 cells and CD68+ macrophages.3 Kerati-
nocyte-derived interleukin (IL)-1a is a key early mediator of
inﬂammation and comedogenesis.4 However, P. acnes appears
capable of inducing the production of a variety of pro-
inﬂammatory cytokines such as IL-8, tumour necrosis factor
(TNF)-a, granulocyte–monocyte colony-stimulating factor and
IL-12p40 by peripheral blood mononuclear cells (PBMCs)5,6
and ⁄or keratinocytes.7
These ﬁndings have led to the perception that acne is asso-
ciated with the dysregulation of the pro-inﬂammatory
response to P. acnes. One potential counter-regulatory cytokine
is IL-10, which profoundly inhibits many macrophage and
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dendritic cell functions by downregulating antigen presenta-
tion as well as the production of cytokines, chemokines, nitric
oxide, reactive oxygen species and co-stimulatory mole-
cules.8,9 Speciﬁcally, IL-10 is a strong inhibitor of IL-12 pro-
duction in the skin and likely acts to contain excessive dermal
inﬂammation.10 Consequently, there is considerable interest in
the role of IL-10 in a number of skin disorders both as a po-
tential mediator of pathological change and as a therapeutic
agent.11
The main cellular sources of IL-10 include CD14+ macro-
phages, as well as Th2 and T-regulatory (Treg) lymphocytes,
which mediate peripheral tolerance.12,13 IL-10 levels increase
in acne comedones after ultraviolet irradiation and induce a
functional deﬁciency of antigen-presenting cells including Lan-
gerhans cells.14 This may explain why sunlight has beneﬁcial
effects on acne in some patients. Although IL-10, as well as
TNF-a and IL-8, is reported to be upregulated in established
inﬂamed lesions,15 its role in the control of early inﬂamma-
tory events by newly recruited cells from the blood is not
known.
Thus, there is a need for a greater understanding of the in-
ﬂammatory response in acne and particularly the role of
immunoregulatory IL-10. This study focused on the extent
and cellular source of IL-10 secretion by PBMCs from patients
with acne and healthy controls in response to P. acnes. The
study demonstrates that IL-10 production by PBMCs, in partic-
ular CD14+ cells, is signiﬁcantly lower in patients with acne.
This highlights a potentially important role for this cytokine
in regulating the inﬂammatory response to P. acnes within
follicles.
Patients and methods
Patients and controls
Individuals participating in this study were 47 patients with
acne (27 males and 20 females with a mean age of 19, range
16–26 years) and 40 controls (15 males and 25 females with
a mean age of 20, range 16–26 years). Patients were graded
for their acne according to the Leeds scale16 and were free of
topical or systemic therapy for at least 2 weeks prior to blood
collection. Ethical approval for this project was given by the
Research Ethics Committee of Harrogate District Hospital (REC
number: 05 ⁄Q1107 ⁄78). The study was conducted according
to the principles of the Declaration of Helsinki and written
informed consent was obtained from all participants.
Bacterial culture
A single colony population of P. acnes (NCTC 737) was incu-
bated at 37 C for 2–3 days in Wilkins Chalgren anaerobic
broth (Sigma-Aldrich Ltd, Poole, U.K.), washed three times,
resuspended in NaCl (0Æ9%) and then frozen at )80 C until
further use. The viability of P. acnes after freezing was veriﬁed
and it was determined that 100 lg bacteria was equivalent to
2 · 106 CFU.
Isolation of peripheral blood mononuclear cells and
in vitro culture
Venous blood (20 mL) was layered onto an equal volume of
Histopaque (Sigma-Aldrich Ltd) and centrifuged for 30 min at
400 g. The PBMC interface layer was washed and then
cultured at 2 · 105 cells per well in RPMI 1640 supplemented
with 10% low endotoxin fetal calf serum (Biosera, Ringmer,
East Sussex, U.K.), 1% L-glutamine (200 nmol L)1) and 1%
penicillin ⁄streptomycin (10 000 U mL)1) (Gibco, Paisley,
U.K.). Cells were stimulated with P. acnes (0Æ1–100 lg mL)1),
anti-CD3 monoclonal antibody (mAb); (0Æ5 lg mL)1; R & D
Systems, Abingdon, U.K.), or lipopolysaccharide (LPS) (from
Escherichia coli 0111 B4, 500 ng mL)1, Sigma-Aldrich Ltd) at
37 C and 5% CO2. The lowest concentrations of P. acnes (0Æ1
and 1Æ0 lg mL)1) were tested on only a limited number
(~16–20) of subjects, hence the variable number of patients
given for different bacterial doses. PBMCs were cultured with
live P. acnes without antibiotics.
Analysis of peripheral blood mononuclear cell
proliferation and cytokine detection
Cell supernatants were collected at 24 and 72 h, and following
storage at )20 C, were analysed for the presence of IL-8,
IL-10, IL-12 ⁄23p40 and TNF-a using enzyme-linked immu-
nosorbent assay (ELISA) detection kits (IL-8 kit from Biosource
Europe SA, Nivelles, Belgium; others from R & D Systems).
After 72 h culture, cells were incubated for a further 18 h in
the presence of 3[H]-thymidine at 0Æ2 lCi per well (Amer-
sham plc, Amersham, Bucks, U.K.). Cell cultures were then
harvested using a Filtermate Harvester (Packard Bioscience BV,
Groningen, the Netherlands) and the incorporation of radio-
isotope into cellular DNA determined using a TopCount
NXTTM scintillation counter (Packard Bioscience BV) and
expressed as mean stimulation index (± SEM) of c.p.m. for
stimulated cells over unstimulated cells for each control and
patient.
Intracellular interleukin-10 staining and analysis by flow
cytometry
PBMCs were cultured for 48 h, the last 5 h of which were in
the presence of 0Æ5 lL per well Golgi Stop (BD Pharmingen,
Oxford, U.K.). Cells were then washed and stained with
ﬂuorochrome-conjugated antibodies [diluted in phosphate-
buffered saline (PBS) containing 10% bovine serum albumin]
for 30 min at 4 C. Antibodies were as follows: Paciﬁc Blue-
anti-human CD4 (clone OKT4), ﬂuorescein–isothiocyanate-
anti-CD19 (clone HIB19), biotin–anti-CD14 (clone 61D3; all
BD Pharmingen) followed by PECy7-labelled streptavidin
(eBioscience, Hatﬁeld, U.K.), or the appropriate labelled iso-
type control antibodies. Cells were then treated with Cytoﬁx ⁄
Cytoperm kit (BD Pharmingen) and stained with Alexa
Fluor 647-anti-human IL-10 mAb (clone JES3-9D7) or the
corresponding isotype control, for 30 min at 4 C. Cells were
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analysed using a Cyan II ﬂow cytometer (DakoCytomation,
Ely, U.K.) with SummitTM software.
Phagocytosis of Propionibacterium acnes in vitro by
peripheral blood mononuclear cells
P. acnes cells were stained using Alexa Fluor 488 TFP (Alexa
Fluor 488; Invitrogen, Paisley, U.K.) for 30 min in the dark
at 37 C. Following 1 h incubation in cold PBS in the dark to
remove unbound dye, labelled P. acnes were added to PBMCs
for 45 min in the dark. Cells were then labelled with anti-
CD14 antibody, and phagocytosis determined as the number
of CD14+ cells also positive for Alexa Fluor 488. In some
experiments, PBMCs were pre-incubated with recombinant
human IL-10 (10 ng mL)1; R & D Systems) for 2 h prior to
the addition of P. acnes at 10 or 100 lg mL)1. Cell culture
supernatants were analysed for IL-8, IL-12p40 and TNF-a by
ELISA as above after 24 h stimulation.
Statistical analysis
Statistical comparison between patient and control samples
for each experiment was made using a Mann–Whitney U-test.
Values of P < 0Æ05 were considered signiﬁcant.
Results
Levels of interleukin-12, tumour necrosis factor-a and
interleukin-8 are similar, or elevated in patients with
acne
In healthy controls and patients with acne, the secretion of
pro-inﬂammatory IL-12p40 by PBMCs was actively stimulated
by increasing concentrations of P. acnes with a peak response at
10 lg mL)1 (492 ± 68 pg mL)1, Fig. 1a). However, there
was no signiﬁcant difference in the secretion proﬁle between
patients and controls. There was also little difference in the
secretion of TNF-a in response to either LPS or low concentra-
tions of P. acnes between patients with acne and healthy con-
trols, although when stimulated with 10 or 100 lg mL)1
P. acnes the level of TNF-a detected was signiﬁcantly higher for
PBMCs from patients with acne (both P < 0Æ05). In response
to P. acnes, IL-8 secretion was produced in a dose-dependent
manner (Fig. 1c). Moreover, PBMCs from patients with acne
in the presence of LPS or P. acnes (at 1 lg mL)1 and
10 lg mL)1) secreted signiﬁcantly more IL-8 than PBMCs
from healthy controls (P < 0Æ05).
Secretion of the downregulatory cytokine interleukin-10
by peripheral blood mononuclear cells in response to
Propionibacterium acnes is significantly lower in patients
with acne
The peak of IL-10 production was detected at 72 h (data not
shown) and secretion in response to P. acnes increased in a
dose-dependent manner and reached a plateau at 10 lg mL)1
in patients with acne and a maximum at 100 lg mL)1 in con-
trols (Fig. 2a). However, IL-10 secretion was signiﬁcantly
lower in patients with acne compared with controls (e.g. at
10 lg mL)1, 976 ± 102 cf. 766 ± 112 pg mL)1; and at
100 lg mL)1, 1498 ± 210 cf. 807 ± 103 pg mL)1 for
patients with acne and healthy controls, respectively; both
P < 0Æ05). Indeed, the level of the IL-10 response was on
average 46% lower in patients with acne compared with con-
trols for stimulation with P. acnes at 100 lg mL)1. Similarly,
signiﬁcantly less IL-10 was also secreted in response to LPS in
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Fig 1. Peripheral blood mononuclear cells (PBMCs) from patients
with acne secrete similar or greater amounts of pro-inﬂammatory
cytokines than PBMCs from controls. (a) The secretion of interleukin
(IL)-12p40 in patients with acne (n = 26–41) and controls
(n = 16–36); (b) tumour necrosis factor (TNF)-a (patients n = 20–28;
controls, n = 12–25); and (c) IL-8 (patients, n = 21–32; controls,
n = 11–28) was measured by enzyme-linked immunosorbent assay
where n values are greatest for P. acnes concentration of 10 and
100 lg mL)1 and lowest for 0Æ1 and 1 lg mL)1. Results are expressed
as the mean ± SEM. *P £ 0Æ05.
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patients with acne when compared with the control PBMC
response (541 ± 66 cf. 895 ± 122 pg mL)1; P < 0Æ05). No
sex- or age-related difference in the production of IL-10 was
demonstrated (data not shown).
In order to identify a possible correlation between acne dis-
ease severity and IL-10 secretion in response to P. acnes, patient
PBMCs were divided into two groups according to the severity
of acne: mild acne with a grade £ 1, and moderate to severe
acne with a grade > 1 (scored according to the scale of Burke
and Cunliffe16). No difference in the level of IL-10 secretion
was observed between patients with mild acne (n = 19) and
those with moderate to severe acne (n = 16) (data not shown).
Interleukin-10+ peripheral blood mononuclear cells are
less abundant in patients with acne
In resting healthy PBMCs, IL-10 was not detected, or at only a
very low level (~0Æ2% Fig. 3a, c). However, when stimulated
with 10 lg mL)1 of P. acnes, the detection of IL-10+ PBMCs
was increased four-fold such that ~1Æ0% of the total PBMC
population was positive for this cytokine. Although these values
appear low, over 50 000 events were analysed by ﬂow cyto-
metry giving conﬁdence that the observed changes are signiﬁ-
cant. The percentage of IL-10+ PBMCs in patients with acne
was low (0Æ3%) after stimulation with 10 lg mL)1 P. acnes, and
was signiﬁcantly lower when compared with PBMCs from
healthy controls (P < 0Æ05; Fig. 3b, c). Similar results were
obtained using a higher stimulation dose of 100 lg mL)1
P. acnes (P < 0Æ05). Overall, there were about 60% fewer IL-10+
PBMCs from patients with acne than healthy controls (Fig. 3c).
Proliferation of peripheral blood mononuclear cells from
patients with acne and healthy controls is similar
The proliferative response of PBMCs to P. acnes was evaluated in
order to determine whether the difference in IL-10 production
was a reﬂection of PBMC proliferation. P. acnes induced the
proliferation of PBMCs from healthy controls and patients with
acne to a similar extent, with mean stimulation indices,
respectively, of 7Æ6 ± 1Æ1 and 9Æ2 ± 1Æ2 over unstimulated
cells for a dose of 10 lg mL)1 but they were not statistically
different (all P > 0Æ05; Fig. 4). In comparison, anti-CD3 mAb
induced far higher levels of cell proliferation leading to stimu-
lation indices of 65Æ1 ± 8Æ7 and 77Æ7 ± 7Æ2 for control and
patient PBMCs, respectively, but again they were not signiﬁ-
cantly different.
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Fig 2. Interleukin (IL)-10 secretion by peripheral blood mononuclear
cells (PBMCs) is signiﬁcantly lower in patients with acne than in
healthy controls. PBMCs incubated for 72 h in the absence or presence
of lipopolysaccharides (LPS) or P. acnes (0Æ1, 1, 10 or 100 lg mL)1).
IL-10 levels were detected by enzyme-linked immunosorbent assay.
Results are expressed as the mean ± SEM (n = 20–40 for controls,
n = 25–39 for patients). *P £ 0Æ05.
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Patients with acne have significantly fewer
interleukin-10+ CD14+ peripheral blood mononuclear
cells
In healthy controls, the vast majority of IL-10+ PBMCs were
CD14+ (51Æ6 ± 9%). The percentage of IL-10+ PBMCs that
were CD4+ or CD19+ remained small, even after stimulation
with P. acnes (15Æ9 ± 4Æ8% and 7Æ8 ± 1Æ5%, respectively;
Fig. 5). The remaining 25% were CD14) CD4) CD19), and
possibly represent inactivated B cells, CD8+ cells, NK cells or
CD14) macrophages. Examination of the CD14+ PBMC popu-
lation from healthy individuals showed that when stimulated
with 10 lg mL)1 P. acnes, 5Æ05 ± 0Æ83% were IL-10+
(Table 1). This is signiﬁcantly higher than in patients with
acne where only 2Æ07 ± 0Æ77% were IL-10+ (P < 0Æ05). How-
ever, no signiﬁcant change between patients with acne and
healthy controls in the proportion of IL-10+ PBMCs were
observed for CD19+ or CD4+ populations (both P > 0Æ05).
This suggests that the deﬁciency in IL-10 production in
patients with acne is conﬁned to the CD14+ cell population
and is not evident in CD4+ T or CD19+ B lymphocytes.
The phagocytic activity of CD14+ peripheral blood
mononuclear cells is significantly reduced in patients
with acne, but is restored by the addition of exogenous
interleukin-10
The phagocytic activity of CD14+ PBMCs was examined
in light of their ability to take up Alexa Fluor 488 labelled
P. acnes. It was observed that CD14+ cells from patients with
acne phagocytosed signiﬁcantly fewer labelled P. acnes than
cells from healthy controls (i.e. ~20% cf. 40%) (Fig. 6a–c,
P < 0Æ01). Furthermore, the addition of IL-10 to PBMC
cultures increased the uptake of P. acnes by CD14+ cells from
patients with acne by approximately two-fold (P < 0Æ01), to a
level similar to that seen in healthy controls (Fig. 6a–c). Sup-
plementation of IL-10 to cultures of PBMCs from healthy con-
trols had no signiﬁcant impact on their ability to phagocytose
P. acnes (P > 0Æ05). The addition of IL-10 to PBMCs from acne
and healthy controls stimulated with P. acnes (10 lg mL)1)
also led to a reduced secretion of IL-8 (Fig. 6d) while the
effect of IL-10 supplementation on TNF-a secretion by PBMCs
stimulated with P. acnes (10 lg mL)1) was more pronounced
with a reduction of 78% and 62% for PBMCs from patients
with acne and healthy controls, respectively (Fig. 6e).
Discussion
The aim of this study was to investigate the inﬂammatory
cytokine response of PBMCs from patients with acne vulgaris
following stimulation with P. acnes. The production of the pro-
inﬂammatory cytokines IL-8, TNF-a and IL-12p40 were either
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Fig 4. Proliferation of peripheral blood mononuclear cells (PBMCs)
from patients with acne and healthy controls in response to mitogen
and P. acnes stimulation. PBMCs were cultured for 72 h in the presence
or absence of aCD3 monoclonal antibody, lipopolysaccharide (LPS) or
P. acnes (0Æ1, 1, 10 and 100 lg mL)1). The incorporation of [3H]
thymidine was measured in c.p.m. Results are expressed as the
mean ± SEM (n = 20–40 for controls, n = 19–33 for patients).
*P £ 0Æ05.
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Fig 5. The majority of interleukin (IL)-10+ cells are CD14+. Relative
contribution of CD4+, CD19+ and CD14+ cells in the detection of
IL-10 in healthy controls peripheral blood mononuclear cells (PBMCs)
treated with P. acnes (10 lg mL)1). CD14+ cells are the major source
of IL-10. Similar proportions were observed for patients with acne
PBMCs.
Table 1 The percentage of IL-10+ CD14+ cells cultured in the absence
or presence of P. acnes is lower in patients with acne
CD14+ CD19+ CD4+
Medium only
Controlsa 0Æ92 ± 0Æ25 0Æ54 ± 0Æ10 0Æ31 ± 0Æ08
Patientsa 1Æ10 ± 0Æ17 0Æ32 ± 0Æ08 0Æ28 ± 0Æ08
P. acnes (10 lg mL)1)
Controls 5Æ05 ± 0Æ83 0Æ61 ± 0Æ14 0Æ39 ± 013
Patients 2Æ07 ± 0Æ77* 0Æ65 ± 0Æ15 0Æ33 ± 0Æ09
P. acnes (100 lg mL)1)
Controls 4Æ36 ± 0Æ72 0Æ68 ± 0Æ17 0Æ19 ± 0Æ04
Patients 3Æ09 ± 0Æ57 0Æ53 ± 0Æ19 0Æ36 ± 0Æ12
an = 8; *P < 0Æ05 for patients compared with controls; bold,
statistically signiﬁcant.
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slightly elevated or unchanged in patients with acne when
compared with healthy controls. However, a statistically
signiﬁcant reduction in PBMC secretion of anti-inﬂammatory
IL-10 in patients with acne was identiﬁed. The impaired
production of IL-10 by PBMCs from patients with acne was
conﬁned to CD14+ cells that were also defective in their ability
to phagocytose P. acnes bacteria. The addition of exogenous
IL-10 to PBMC cultures from patients with acne restored
phagocytic activity.
To our knowledge, this study is the ﬁrst to report a
signiﬁcant imbalance in the production by PBMCs of pro- and
anti-inﬂammatory cytokines between patients with acne and
healthy controls. The secretion of both IL-8 and TNF-a by
PBMCs was signiﬁcantly elevated in patients with acne in
agreement with studies elsewhere.17 The production of these
cytokines in response to P. acnes stimulation is linked to the
expression of innate immune response pattern recognition
receptor TLR2.5,18,19 However, no difference was detected in
the secretion of the p40 subunit of the pro-inﬂammatory
cytokine complex IL-12 ⁄ IL-23. This conﬂicts with ﬁndings
that IL-12 originating from monocytes was increased follow-
ing stimulation with P. acnes via TLR2,5,19 but agrees with the
observation that IL-12p40 mRNA is not upregulated in acne
lesions compared with uninvolved skin.15
In contrast to the upregulation of pro-inﬂammatory cyto-
kines, the production of the anti-inﬂammatory cytokine IL-10
was markedly downregulated in patients with acne in this
study. IL-10 is a well-described regulatory cytokine that acts
to harness the release of several pro-inﬂammatory cytokines.20
In our study, it appears to act primarily on TNF-a but has
ittle effect upon IL-12. Therefore, we speculate that in patients
with acne, early activation of the immune response is not
controlled, due to the relative paucity of IL-10. As a result,
inﬂammation is pathologically sustained in patients with acne
contributing to the events that lead to the initiation and ⁄or
persistence of inﬂammatory lesions. On the other hand, there
was no association between the severity of acne and the abso-
lute quantity of secreted IL-10. This might suggest that a rela-
tive deﬁciency of IL-10 predisposes a patient to acne, but
cannot be used to predict the severity of the clinical lesions. It
may also suggest that a lack of IL-10 cannot solely predict the
severity of acne. Indeed, it is well known that acne is multi-
factorial and it would be surprising if it could be completely
explained through the actions of a solitary cytokine.21
IL-10 can derive from CD4+ T cells with regulatory func-
tion (so-called Tregs).
12,22 However, aCD3 mAb stimulation
did not affect the differential secretion of IL-10 between
PBMCs derived from patients with acne and controls. We also
show that CD4+ cells are only a minor (~16%) source of
IL-10 and the proportions of IL-10+ CD4+ cells do not differ
between control and patient PBMCs. Therefore, we conclude
that IL-10-producing Tregs among the PBMC population are
unlikely to have a major role in determining the propensity to
develop acne.
The most abundant IL-10+ cell population among PBMCs
were CD14+ (> 50%) and these are under-represented in
patients with acne. CD14+ PBMCs are a well-described source
of IL-10.23 In the skin, the main sources of IL-10 in the early
phase of inﬂammation are CD14+ cells,15 possibly originating
from the peripheral blood. TLR2 expression on CD14+ cells is
also increased in cells localized within acne lesions.5,24 The role
of IL-10 is likely the downregulation of pro-inﬂammatory
cytokines as demonstrated by the decreased production of IL-8
and TNF-a after the addition of exogenous IL-10 to PBMC cul-
tures. However, IL-10 is known to be markedly upregulated in
established acne lesions.15 This appears to contradict the ﬁnd-
ings presented here. We speculate that the CD14+ PBMCs
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Fig 6.2 CD14+ peripheral blood mononuclear cells (PBMCs) from
patients with acne phagocytose less P. acnes than cells from healthy
controls, and levels of phagocytosis are restored by the addition of
exogenous interleukin (IL)-10. PBMCs from healthy controls and from
patients with acne (n = 4) were stimulated with Alexa Fluor 488
labelled P. acnes in the presence or absence of recombinant IL-10. The
level of phagocytosis was determined by the uptake of labelled P. acnes
by CD14+ PBMCs from (a) a healthy control or (b) an acne patient as
determined by ﬂow cytometry. (c) The addition of IL-10 to PBMCs
from patients with acne restored levels of phagocytosis of P. acnes to
levels seen in healthy controls and reduced the production of (d) IL-8
and (e) TNF-a. Data were normalized by a log10 for statistical
analysis (P-values: **P £ 0Æ01).
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represent a set of circulating monocytes ⁄ immature macrophages
that will be the ﬁrst to inﬁltrate the tissue around a develop-
ing lesion. Dysregulation in IL-10 production by these circulat-
ing CD14+ cells may facilitate the development of intense
inﬂammatory lesions driven by an imbalance towards pro-
inﬂammatory cytokines such as TNF-a and IL-8. Therefore, a
deﬁcit in the number of IL-10-producing CD14+ monocytes, as
seen in our patients with acne, would favour the development
of an inﬂammatory cascade characteristic of acne lesions. In
established lesions, CD68+ mature macrophages will predomi-
nate3 and only then is IL-10 ﬁnally produced in an attempt to
regulate the overactive inﬂammatory response.
The cause of the differences in the production of IL-10
between healthy controls and patients with acne is uncertain.
There is known to be considerable inter-individual variation
in the capacity of human PBMCs to produce IL-10, with at
least 50% likely due to genetic factors.25 Polymorphisms of
the 5¢-ﬂanking region of the IL-10 gene26 and single nucleo-
tide polymorphisms within the promoter region have been
linked with a number of chronic dermatoses including psoria-
sis.27,28 Unfortunately, a detailed genetic analysis was beyond
the scope of the current study but the familial inheritance of
acne may be partly explained by this mechanism. Our study
also raises questions about the onset and resolution of acne.
Onset commonly occurs during adrenarche when output of
dihydroepiandrosterone (DHEA) starts to rise.29 The relation-
ship between DHEA, IL-10 and progression to acne has not
been investigated, although data in humans indicate there may
be a negative correlation between serum IL-10 levels and
DHEA concentration.30,31 The resolution of acne in individuals
may represent upregulation of IL-10 expression and it would
be important to perform a longitudinal study to determine if
the course of acne relates to changes of IL-10 with age. Alter-
natively, other mechanisms of immune regulation may evolve
with time and act independently of IL-10 released by CD14+
cells. For example, Treg cells may be involved in the resolution
of acne21 and have been implicated in other skin condi-
tions,32,33 while the delivery of Treg cells can dampen skin
inﬂammation in a model of psoriasis.34 Therefore, it is
reasonable to assume that Treg cells may downregulate the
CD4+ T-cell response to P. acnes and thus explain why resolu-
tion can occur even in the presence of reduced IL-10 produc-
tion by PBMCs.
Administration of exogenous IL-10 in vivo is reported to be
an effective therapeutic strategy in controlling skin disorders
such as psoriasis.35 This study raises the possibility that the
same treatment strategy may be a feasible approach in acne.
Moreover, and perhaps counterintuitively in light of its down-
regulatory functions, administration of IL-10 to in vitro cultures
of PBMCs from patients with acne increased the phagocytic
process allowing CD14+ cells to take up more P. acnes. Thus,
in addition to limiting the levels of pro-inﬂammatory cyto-
kines and so preventing a ‘hyper-immune response’, as seen
in patients with acne, IL-10 also acts to facilitate phagocytosis
by CD14+ cells36 and presumably results in more effective
clearance of P. acnes.
In summary, these data suggest that acne lesions may
develop because of a defect in immunosurveillance. We pro-
pose that an immune response to P. acnes bacteria in the follicle
is usually dampened by PBMC-derived IL-10 before visible in-
ﬂammation develops. Reduced production of IL-10 by CD14+
PBMCs, most likely monocytes, predisposes to unchecked pro-
inﬂammatory changes. This interpretation raises the possibility
that acne therapeutics might proﬁtably target IL-10 both as a
regulator of pro-inﬂammatory cytokines and in augmenting
the CD14+ cell phagocytic response. Future studies should
seek to characterize the cellular sources of IL-10 in evolving
and healing acne lesions and compare the skin distribution of
IL-10 in subjects with acne and subjects whose acne has
resolved spontaneously.
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